Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation

Trial Profile

Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2017

At a glance

  • Drugs Anti-CD45 monoclonal antibody BC8 I-131 (Primary) ; Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Refractory anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 18 Jul 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top